- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06872255
Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA)
A Prospective Pilot Trial of Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA Trial)
Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. The investigators plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jan Martínek, prof., MD
- Numéro de téléphone: +420 723 708 839
- E-mail: jan.martinek@fnusa.cz
Sauvegarde des contacts de l'étude
- Nom: Martin Vašátko, MD
- Numéro de téléphone: +420 739 476 451
- E-mail: martin.vasatko@fnusa.cz
Lieux d'étude
-
-
-
Trnava, Slovaquie, 91701
- Pas encore de recrutement
- University Hospital Trnava
-
Contact:
- Rastislav Husťak, MD
- Numéro de téléphone: +421 33/593 81 11
- E-mail: rhustak@gmail.com
-
Contact:
- Ján Ušák, MD
- Numéro de téléphone: +421 33/593 81 11
- E-mail: jan.usak@gmail.com
-
-
Slovakia
-
Martin, Slovakia, Slovaquie, 03601
- Recrutement
- Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin,
-
Contact:
- Martin Duricek, Ass. Prof
- Numéro de téléphone: +421 4203 973
- E-mail: martin.duricek@gmail.com
-
Contact:
- Peter Banovcin, Ass. Profesor
- Numéro de téléphone: +421 4203 448
- E-mail: pbanovcin@gmail.com
-
-
-
-
-
Brno, Tchéquie, 60200
- Recrutement
- St. Anne's University Hospital Brno, Czech Republic
-
Contact:
- Jan Martínek, prof., MD
- Numéro de téléphone: +420 723 708 839
- E-mail: jan.martinek@fnusa.cz
-
Contact:
- Martin Vašátko, MD
- Numéro de téléphone: +420 739 476 451
- E-mail: martin.vasatko@fnusa.cz
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment.
- Refractory (> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline.
- X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial/total stagnation of the contrast solution above the GEJ
- Endoluminal planimetry: EGJ-DI < 3 mm2/mmHg (with 40ml)
- Age above 18 years
- Signed informed consent form
Exclusion Criteria:
- No previous attempt with at least one prokinetic drug
- Previous esophageal myotomy (open, laparoscopic or endoscopic)
- Primary esophageal motility disorder (achalasia etc.)
- Active erosive esophagitis
- Active peptic ulcer disease
- Esophageal stricture (peptic, malignant, other)
- Partial or complete supradiaphragmatic migration of the wrap and/or stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm
- Known eosinophilic esophagitis
- Severe coagulopathy
- Esophageal or gastric varices
- Advanced liver cirrhosis (Child B or Child C)
- Pregnancy or puerperium
- Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment
- Any other condition, which in the opinion of the investigator would interfere with study requirements
- Known gastroparesis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: POEM arm
Patients, who will undergo peroral endoscopic myotomy for postfundoplication dysphagia |
All procedures will be performed by an experienced endoscopist, with a sufficient experience in "third space" endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy POEM in patients with postfundoplication dysfagia
Délai: 6 months
|
The primary outcome will be proportion of patients with treatment success defined as Eckardt score ≤ 2 and its decrease by at least 1 point after POEM at 6 months |
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Eckardt score
Délai: At baseline, 3, 6 and 12 months
|
The Eckardt score is the grading system used for the evaluation of severity of symptoms in patients with esophageal achalasia. Four symptoms are assessed (dysphagia, regurgitation, chest pain and weight loss) and their severity ranges from 0 (no symptom) to 3 (with every meal). Total score is their sum and ranges from 0 to 12 |
At baseline, 3, 6 and 12 months
|
|
Mellow - Pinkas score
Délai: At baseline, 3, 6 and 12 months
|
The Mellow - Pinkas score is used to assess dysphagia grade before and after the interventions. Total score ranges from 0 to 3 (0 = able to eat normal diet, 1 = able to swallow some solid foods, 2 = able to swallow only semi solid foods, 3 = able to swallow liquids only) |
At baseline, 3, 6 and 12 months
|
|
PAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)
Délai: At baseline, 3, 6 and 12 months
|
The PAGI-QoL questionnaire contains of 30 items with five subscales: (1) daily activities; (2) clothing; (3) diet/food habits; (4) relationship; and (5) psychological well-being and distress. Each item is scored on a 6-point Likert scale, with response options ranging from 0 (none) to 5 (severe problem all of the time). Subscale scores are calculated by averaging the item responses. A total score is calculated by averaging subscale scores. Higher score means impairment in quality of life. |
At baseline, 3, 6 and 12 months
|
|
GERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)
Délai: At baseline, 3, 6 and 12 months
|
The GERD-HRQL questionnaire was developed and validated to measure changes of typical GERD symptoms such as heartburn and regurgitation in response to surgical or medical treatment. Higher (greater) possible score means worst symptoms - ranging from 0 to 75. |
At baseline, 3, 6 and 12 months
|
|
Integrated Relaxation Pressure (IRP)
Délai: At baseline, at 6 months
|
High resolution manometry - Median IRP recorded from 10 supine swallows, measured in mmHg. A value >15 mmHg indicates EGJ outflow obstruction. |
At baseline, at 6 months
|
|
Endoluminal planimetry (Endoflip)
Délai: At baseline, ať 6 months
|
Pyloric distensibility measured by impedance planimetry (EndoFLIP device) |
At baseline, ať 6 months
|
|
Esophagogram
Délai: At baseline, at 6 months
|
Esophagogram provides valuable information of the fundoplication, better appreciate a paraesophageal hernia and information on esophageal emptying. Patients will be advised overnight fasting prior to timed barium esophagogram. A contrast agent (e.g. barium, usually 100 to 250 mL) is ingested orally within 15-20 seconds. Left posterior oblique X-ray will be taken 2 and 5 minutes after contrast agent ingestion. Maximum esophageal width and column hights will be recorded at 2 and 5 minutes. |
At baseline, at 6 months
|
|
Eckardt score
Délai: At baseline, 3 and 12 months
|
The Eckardt score is used to assess the severity of achalasia symptoms. It is based on the four main symptoms of achalasia: dysphagia, regurgitation, chest pain and weight loss. Each symptom has four levels of severity: none = 0 point, occasional = 1 point, daily = 2 points, each meal = 3 points. The sum of the points gives the final score. Final score scale: 0 (best) - 12 (worst). Treatment success is defined as a decrease of Eckardt score by at least 1 point and an overall Eckardt score ≤ 2. |
At baseline, 3 and 12 months
|
|
GERD
Délai: At baseline, 3, 6 and 12 months
|
Presence of reflux esophagitis based on endoscopy findings. |
At baseline, 3, 6 and 12 months
|
|
Esophageal 24h-Hour pH metry
Délai: At 3 months after procedure
|
An esophageal pH test measures how often stomach acid enters to the esophagus. It also measures how long the acid stays there. The test involves placing a catheter into the esophagus. The catheter or device will measure an acid level (known as pH level) for 24 hours. Post-POEM Esophageal acid exposure (DeMeester score, proportion of time with pH below 4)After |
At 3 months after procedure
|
|
PPI/H2 antagonists
Délai: At baseline, 3, 6 and 12 months
|
PPI's and/or H2 antagonists use before and after procedure (POEM). |
At baseline, 3, 6 and 12 months
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- VADYSMA
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .